Skip to main content
SpringerLink
Log in

Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Alpha-fetoprotein (AFP) has been used as a diagnostic biomarker for hepatocellular carcinoma (HCC), but its prognostic significance is not well defined. This study was performed to classify the prognostic significance of AFP status in HCC patients after transarterial chemoembolization (TACE).

Methods

Four hundred forty-one HCC patients from a prospective maintained database with pathologic confirmation including 139 with normal AFP levels and 302 with elevated AFP levels were retrospectively studied for prognostic significance of AFP in treatment response and survival after TACE. Univariate and multivariate analyses were used to identify the prognostic factors.

Results

There were significant differences in overall survival (OS) after TACE between AFP-negative and AFP-positive HCC patients when the AFP cutoff value was defined as 20 ng/ml (P < 0.0001). Among the AFP-positive patients, different AFP levels had no significantly prognostic effects on OS after TACE (P = 0.093). Multivariate analysis revealed that AFP status for AFP-negative or positive was an independent prognostic factor for HCC patients after TACE (P = 0.001), along with γ-glutamyltransferase (GGT) level (P = 0.004) and tumor diameter (P < 0.0001). In addition, there were significant differences in clinicopathologic features between AFP-positive and AFP-negative patients with regard to age, gender, alanine transferase level, GGT level, tumor diameter, and Barcelona Clinic Liver Cancer stage.

Conclusions

Compared with AFP-positive HCC patients, patients with AFP-negative status have a better treatment response and prognosis after TACE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–58.

    Article  PubMed  Google Scholar 

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  4. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  5. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  PubMed  CAS  Google Scholar 

  6. Amarapurkar D, Han KH, Chan HL, Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia–Pacific region. J Gastroenterol Hepatol. 2009;24:955–61.

    Article  PubMed  Google Scholar 

  7. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19–26.

    Article  PubMed  CAS  Google Scholar 

  8. Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795–804.

    Article  PubMed  Google Scholar 

  9. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446–52.

    Article  PubMed  CAS  Google Scholar 

  10. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734–42.

    Article  PubMed  CAS  Google Scholar 

  11. Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590–6.

    Article  PubMed  CAS  Google Scholar 

  12. Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223–32.

    Article  PubMed  CAS  Google Scholar 

  13. Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:111–7.

    Article  PubMed  CAS  Google Scholar 

  14. Toyoda H, Kumada T, Osaki Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–36.

    Article  PubMed  CAS  Google Scholar 

  15. Pompili M, Rapaccini GL, Covino M, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer. 2001;92:126–35.

    Article  PubMed  CAS  Google Scholar 

  16. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524–32.

    Article  PubMed  CAS  Google Scholar 

  17. Kohles N, Nagel D, Jüngst D, et al. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202.

    Article  PubMed  CAS  Google Scholar 

  18. Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg. 2011;146:26–33.

    Article  PubMed  Google Scholar 

  19. Tsai YJ, Hsu CY, Huang YH, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int. 2011;5:975–84.

    Article  Google Scholar 

  20. Kohles N, Nagel D, Jüngst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33–40.

    Article  PubMed  CAS  Google Scholar 

  21. Mitsuhashi N, Kobayashi S, Doki T, et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189–97.

    Article  PubMed  CAS  Google Scholar 

  22. Yang X, Zhang Y, Zhang L, Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 2008;271:281–93.

    Article  PubMed  CAS  Google Scholar 

  23. Li M, Zhou S, Liu X, et al. Alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor–related apoptosis-inducing ligand. Cancer Lett. 2007;249:227–34.

    Article  PubMed  CAS  Google Scholar 

  24. Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62(Suppl 1):57–63.

    Article  PubMed  CAS  Google Scholar 

  25. Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol. 2010;10:146.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Supported in part by grants from the National Natural Science Foundation of China (30672416) and National Basic Research Program of China (973 Program, 2009CB521700).

Disclosure

The authors have no conflict to disclose.

Author information

Authors and Affiliations

  1. Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, People’s Republic of China

    Yan Wang MD, Yi Chen MD, PhD, Ningling Ge MD, PhD, Lan Zhang MD, Xiaoying Xie MD, Jubo Zhang MD, PhD, Rongxin Chen MD, PhD, Yanhong Wang MD, PhD, Boheng Zhang MD, PhD, Jinglin Xia MD, PhD, Yuhong Gan MD, Zhenggang Ren MD, PhD & Shenglong Ye MD, PhD

Authors
  1. Yan Wang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Chen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ningling Ge MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lan Zhang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoying Xie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jubo Zhang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rongxin Chen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yanhong Wang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Boheng Zhang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jinglin Xia MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuhong Gan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zhenggang Ren MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shenglong Ye MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenggang Ren MD, PhD.

Additional information

Yan Wang and Yi Chen contributed equally to this study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Y., Chen, Y., Ge, N. et al. Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization. Ann Surg Oncol 19, 3540–3546 (2012). https://doi.org/10.1245/s10434-012-2368-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2368-5

Keywords

Search

Navigation